Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2/3 1

Status

Active not recruiting 3Terminated 1Completed 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 7Other hematologic neoplasm 5

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Hematologic Diseases 1

Interventions

Cytarabine 10venetoclax 8Rituximab 7Daunorubicin 7nilotinib 6Azacitidine 6blinatumomab 5Bendamustine Hydrochloride 5bosutinib 4Imatinib Mesylate 4obinutuzumab 3asciminib 3acalabrutinib 3Mitoxantrone 3Methotrexate 3Etoposide 3Dexamethasone 3Decitabine 3Dasatinib 3zanubrutinib 2trametinib 2talquetamab 2revumenib 2pirtobrutinib 2pegaspargase 2ivosidenib 2idelalisib 2ibrutinib 2fludarabine 2decitabine and cedazuridine drug combination 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has announcements × Bendamustine Hydrochloride × Other hematologic neoplasm × Clear all
NCT02970318 2026-05-11

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Acerta Pharma BV

Phase 3 Active not recruiting
310 enrolled 18 charts 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04666038 2026-04-24

BRUIN CLL-321

Eli Lilly and Company

Phase 3 Active not recruiting
238 enrolled 17 charts 1 FDA
LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT03336333 2026-03-09

SEQUOIA

BeOne Medicines

Phase 3 Active not recruiting
590 enrolled 12 charts 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02005471 2023-10-17

MURANO

Hoffmann-La Roche

Phase 3 Completed
389 enrolled 35 charts 2 FDA
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02793583 2022-07-21

UNITY-NHL

TG Therapeutics, Inc.

Phase 2/3 Terminated
710 enrolled 1 FDA
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡